Preview Mode Links will not work in preview mode

Journal of Clinical Oncology recognizes that readers do not always have time to review an article in depth, and yet they still wish to understand how the results will influence their clinical practice or research. To address this need, we offer podcasts that will enhance the readership experience by presenting the key results of high-profile publications in a convenient audio format. Our podcasts are designed to place selected articles into a clinically useful perspective that is easy to listen to in the office or while on the road.

Life is busy, and it’s hard to get it all done during business hours! Journal of Clinical Oncology recognizes that you do not always have time to review an article in depth, and yet you wish to understand how the results will influence your clinical practice or research. JCO After Hours is a podcast intended to enhance the readership experience by presenting key results of high-profile publications in a convenient audio format, placing selected articles into a clinically useful perspective that you can listen to in the office or on the road.

  1. All Episodes
  2. 2011
  3. 04

The Dark Side of del(5q) MDS

Apr 25, 2011

This podcast will discuss the basic background of myelodysplastic syndromes and the clinical implications of TP53 mutations predicting outcomes in del(5q) MDS.

Read More

Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer: Is it Ready for Prime Time?

Apr 18, 2011

This podcast describes the long term outcomes of patients treated with chemotherapy first, followed by either cystectomy or radiation therapy. It provides important information to practicing physicians who treat this disease in helping make decisions about the utility and effectiveness, as well as safety, of using...

Read More

Are Lung Cancers with BRAF Mutations Another Molecularly Defined Subgroup of Patients?

Apr 11, 2011

In this week's podcast, Dr. Jaine discusses the recent manuscript by Paik and colleagues evaluating BRAF mutations in patients with advanced lung cancer. The potential impact of BRAF mutations and outcomes with current therapies for lung cancer are discussed.

Read More

Targeting the VEGF Receptor in Colon Cancer: Lessons Learned from Negative Trials

Apr 4, 2011

In this podcast, Dr. Neal J. Meropol provides his perspective on two large randomized studies of vatalanib in patients with metastatic colorectal cancer.

Read More